CytomX Therapeutics, Inc. - Common Stock (CTMX)
CUSIP: 23284F105
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 169,491,059
- Total 13F shares
- 144,062,799
- Share change
- +5,784,199
- Total reported value
- $613,710,984
- Put/Call ratio
- 5.6%
- Price per share
- $4.26
- Number of holders
- 123
- Value change
- +$47,359,677
- Number of buys
- 74
- Number of sells
- 44
Quarterly Holders Quick Answers
What is CUSIP 23284F105?
CUSIP 23284F105 identifies CTMX - CytomX Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 23284F105:
Top shareholders of CTMX - CytomX Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
|
Company |
15%
|
24,688,109
|
$105,171,344 | +$17,756,285 | 31 Dec 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
9.4%
|
15,561,500
|
$49,641,185 | +$8,195,110 | 30 Sep 2025 | |
| VR Adviser, LLC |
13F
|
Company |
9.2%
|
15,561,500
|
$49,641,185 | — | 30 Sep 2025 | |
| Kynam Capital Management, LP |
13D/G
13F
|
Company |
5.3%
|
8,966,077
|
$48,685,798 | $0 | 31 Dec 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
6.5%
|
11,065,662
|
$35,299,462 | — | 30 Sep 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
13D/G
|
Company |
5.9%
from 13D/G
|
9,680,185
|
$30,879,790 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.3%
|
8,947,807
|
$28,543,505 | — | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
13D/G
|
Company |
2.1%
from 13D/G
|
8,461,500
|
$26,992,185 | — | 30 Sep 2025 | |
| Commodore Capital LP |
13F
|
Company |
4.5%
|
7,692,300
|
$24,538,437 | — | 30 Sep 2025 | |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
|
BVF PARTNERS L P/IL |
3.5%
|
5,769,231
|
$17,250,001 | -$17,250,001 | 03 Jul 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
2.5%
|
4,250,826
|
$13,560,135 | — | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13D/G
13F
|
Company |
2.5%
|
4,068,575
|
$12,978,754 | -$12,811,193 | 30 Sep 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
2.4%
|
4,045,414
|
$12,904,871 | — | 30 Sep 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
2.3%
|
3,913,081
|
$12,482,728 | — | 30 Sep 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
2%
|
3,461,500
|
$11,042,185 | — | 30 Sep 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
2%
|
3,372,616
|
$10,758,645 | — | 30 Sep 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
1.7%
|
2,884,615
|
$9,201,922 | — | 30 Sep 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
1.6%
|
2,661,331
|
$8,489,646 | — | 30 Sep 2025 | |
| Longitude Capital Partners V, LLC |
13D/G
|
— |
7.3%
|
11,538,461
|
$8,192,307 | $0 | 13 May 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.5%
|
2,545,260
|
$8,119,379 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
1.4%
|
2,381,912
|
$7,598,299 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.4%
|
2,337,005
|
$7,455,046 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.1%
|
1,800,435
|
$5,743,387 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.93%
|
1,569,298
|
$5,008,010 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.82%
|
1,386,863
|
$4,424,093 | — | 30 Sep 2025 | |
| Financial Engines Advisors L.L.C. |
13F
|
Company |
0.82%
|
1,381,357
|
$4,406,529 | — | 30 Sep 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.73%
|
1,237,057
|
$3,946,212 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.65%
|
1,104,993
|
$3,524,928 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.59%
|
1,005,228
|
$3,206,677 | — | 30 Sep 2025 | |
| Exome Asset Management LLC |
13F
|
Company |
0.44%
|
745,305
|
$2,377,523 | — | 30 Sep 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.43%
|
729,967
|
$2,328,595 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.43%
|
729,698
|
$2,327,737 | — | 30 Sep 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.39%
|
653,725
|
$2,084,000 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.38%
|
644,982
|
$2,057,493 | — | 30 Sep 2025 | |
| Prosight Management, LP |
13F
|
Company |
0.33%
|
564,800
|
$1,801,712 | — | 30 Sep 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.32%
|
535,974
|
$1,710,000 | — | 30 Sep 2025 | |
| Inspire Investing, LLC |
13F
|
Company |
0.31%
|
522,482
|
$1,666,719 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.27%
|
451,128
|
$1,438,944 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.26%
|
447,753
|
$1,428,332 | — | 30 Sep 2025 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.24%
|
401,891
|
$1,282,032 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.24%
|
401,367
|
$1,280,361 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.23%
|
389,685
|
$1,243,095 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.19%
|
319,288
|
$1,018,529 | — | 30 Sep 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.17%
|
293,560
|
$936,457 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.16%
|
267,485
|
$853,277 | — | 30 Sep 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.15%
|
257,148
|
$820,302 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.15%
|
252,659
|
$805,982 | — | 30 Sep 2025 | |
| Precision Wealth Strategies, LLC |
13F
|
Company |
0.14%
|
237,081
|
$756,288 | — | 30 Sep 2025 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.12%
|
206,526
|
$658,818 | — | 30 Sep 2025 | |
| DIADEMA PARTNERS LP |
13F
|
Company |
0.11%
|
185,286
|
$591,062 | — | 30 Sep 2025 |
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock (CTMX) as of Q4 2025
As of 31 Dec 2025,
CytomX Therapeutics, Inc. - Common Stock (CTMX) was held by
123 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
144,062,799 shares.
The largest 10 holders included
FMR LLC, VR ADVISER, LLC, PERCEPTIVE ADVISORS LLC, Kynam Capital Management, LP, VANGUARD GROUP INC, Commodore Capital LP, Point72 Asset Management, L.P., STATE STREET CORP, BAKER BROS. ADVISORS LP, and ADAR1 Capital Management, LLC.
This page lists
123
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
102
Q4 2025 holders
123
Holder diff
21
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.